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Abstract
Background:  Chronic therapy with nitroglycerin (GTN) results in a rapid development of nitrate
tolerance which is associated with an increased production of reactive oxygen species (ROS). According
to recent studies, mitochondrial ROS formation and oxidative inactivation of the organic nitrate
bioactivating enzyme mitochondrial aldehyde dehydrogenase (ALDH-2) play an important role for the
development of nitrate and cross-tolerance.
Methods: Tolerance was induced by infusion of wild type (WT) and heterozygous manganese superoxide
dismutase mice (Mn-SOD+/-) with ethanolic solution of GTN (12.5 μg/min/kg for 4 d). For comparison, the
tolerance-free pentaerithrityl tetranitrate (PETN, 17.5 μg/min/kg for 4 d) was infused in DMSO. Vascular
reactivity was measured by isometric tension studies of isolated aortic rings. ROS formation and aldehyde
dehydrogenase (ALDH-2) activity was measured in isolated heart mitochondria.
Results: Chronic GTN infusion lead to impaired vascular responses to GTN and acetylcholine (ACh),
increased the ROS formation in mitochondria and decreased ALDH-2 activity in Mn-SOD+/- mice. In
contrast, PETN infusion did not increase mitochondrial ROS formation, did not decrease ALDH-2 activity
and accordingly did not lead to tolerance and cross-tolerance in Mn-SOD+/- mice. PETN but not GTN
increased heme oxygenase-1 mRNA in EA.hy 926 cells and bilirubin efficiently scavenged GTN-derived
ROS.
Conclusion: Chronic GTN infusion stimulates mitochondrial ROS production which is an important
mechanism leading to tolerance and cross-tolerance. The tetranitrate PETN is devoid of mitochondrial
oxidative stress induction and according to the present animal study as well as numerous previous clinical
studies can be used without limitations due to tolerance and cross-tolerance.
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Background
Although organic nitrates such as nitroglycerin (glyceryl
trinitrate, GTN) have been used for over a century in the
therapy of cardiovascular diseases such as stable and
unstable angina [1] the underlying mechanisms of nitrate
bioactivation and development of nitrate tolerance are
not completely understood and are most likely multifac-
torial [2]. Previously, we found that 3 days of nitrate treat-
ment doubled vascular superoxide (O2
-) production [3]
which was also found in human bypass vessels from nitro-
glycerin (GTN) treated patients [4]. The crucial role of oxi-
dative stress for the development of nitrate and cross-
tolerance has been repeatedly demonstrated in numerous
cell culture [5,6], animal [7-10] and human studies [11-
15]. Most beneficial effects of therapeutics on nitrate tol-
erance were based on antioxidative properties [16-18].
In 2002, the mitochondrial aldehyde dehydrogenase
(ALDH-2), which is subject to an oxidative mechanism-
based inactivation, has been identified as a GTN-metabo-
lizing enzyme and a possible important component in the
processes leading to tolerance [19]. This concept was sup-
ported by recent studies in ALDH-2 deficient mice
(ALDH-2-/-) [20]. Our laboratory further substantiated
this concept in an animal model of in vivo tolerance and
extended previous observations by demonstrating that
mitochondria are a major source of ROS formation in
response to acute and chronic GTN challenges [21-23].
The importance of the ALDH-2 concept for clinical nitrate
tolerance was proven by two independent clinical studies
in Asian subjects with a point mutated, dysfunctional
ALDH-2 [24,25].
In the present study, we sought to characterize the role of
mitochondria as a source of superoxide formation for the
development of in vivo nitrate tolerance in response to
GTN. We also used the alternative organic nitrate, PETN,
which has been described to cause no tolerance, to see
whether lack of tolerance induction is associated with a
decrease in ROS formation. We also addressed the initial
steps underlying PETN protective effects which have been
described to be based on induction of heme oxygenase-1
and formation of the potent antioxidant bilirubin
[26,27].
Methods
Materials
PETN (with 80 % (w/w) lactose) was from Fluka (Buchs,
Switzerland). For isometric tension studies, GTN was used
from a Nitrolingual infusion solution (1 mg/ml) from
G.Pohl-Boskamp (Hohenlockstedt, Germany). For induc-
tion of in vivo tolerance, GTN was used from a solution in
ethanol (102 g/l) which was obtained from UNIKEM
(Copenhagen, Denmark). L-012 (8-amino-5-chloro-7-
phenylpyrido [3,4-d]pyridazine-1,4-(2H,3H)dione
sodium salt) was purchased from Wako Pure Chemical
Industries (Osaka, Japan). All other chemicals were of
analytical grade and were obtained from Sigma-Aldrich,
Fluka or Merck.
Animals and in vivo treatment
All animal treatment was in accordance with the Declara-
tion of Helsinki and with the Guide for the Care and Use
of Laboratory Animals as adopted and promulgated by
the U.S. National Institutes of Health and was granted by
the Ethics Committee of the University Hospital Eppen-
dorf and the University Hospital Mainz. We used male
mice aged 7–10 months on a mixed genetic background
(C57Bl/6 × 129/Ola). Experiments were performed with
14 wt and 14 Mn-SOD+/- mice. Mn-SOD+/- mice were gen-
erated according to a published procedure [28] in the lab-
oratory of K. Scharffetter-Kochanek. The deficiency of the
Mn-SOD activity was determined using a specific activity
assay as described recently [28]. In vivo tolerance was
induced by chronic infusion of mice with GTN in ethanol
(25 μg/h, 60 nmol/min/kg for 4 d) by implanted micro-
osmotic pumps (alzet, model 1007D, 0.5 μl/h for 7 d)
from Durect Corp. (Cupertino, CA). Infusion of the sol-
vent ethanol served as a control. We also infused mice
with PETN in DMSO (35 μg/h, 60 nmol/min/kg) or the
solvent alone. After this period, the animals were sacri-
ficed and aorta as well as hearts were subjected to further
analysis. The detailed protocol was recently published
[23]. Wistar rats were either infused with ethanol (1 μl/h
for 4 d) as the solvent control or GTN in ethanol (6.6 μg/
kg/min for 4 d) to induce tolerance as previously pub-
lished [16,22]. In These Wistar rats we used micro-
osmotic pumps (alzet, model 2001, 1 μl/h for 7 d) from
Durect Corp. (Cupertino, CA).
Isometric tension studies
Vasodilator responses to GTN, PETN, ISDN and ACh were
assessed with endothelium-intact isolated murine aortic
rings mounted for isometric tension recordings in organ
chambers upon preconstriction with prostaglandin F2α, as
described previously [29]. It is important to note that the
order of subsequent concentration-relaxation-curves was
ACh, ISDN, GTN (in GTN in vivo treatment group) and
ACh, PETN, GTN (in PETN in vivo treatment group). This
order is important to explain the phenomenon of tach-
yphylaxis induced during tension studies in the organ
baths.
Detection of oxidative stress in isolated heart 
mitochondria
Isolated mitochondria were prepared from mouse hearts
according to a previously published protocol and ROS
formation was detected by L-012 (100 μM) ECL as
recently described [22,23,30]. Briefly, hearts from mice
were homogenized and the 20,000 g pellet was resus-BMC Cardiovascular Disorders 2006, 6:44 http://www.biomedcentral.com/1471-2261/6/44
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pended in Tris buffer. Mitochondrial suspensions were
diluted to a final protein concentration of 0.1 mg/ml in
0.5 ml of PBS buffer containing L-012 (100 μM). ROS pro-
duction was detected after stimulation with succinate (4
mM final concentration). Mitochondria from rat heart
were prepared by a similar procedure and ROS formation
was detected by L-012 ECL as published [31]. Effect of
bilirubin on ROS formation was tested at concentrations
of 0.25–25 μM from a 1 mM stock in DMSO.
ALDH-2 dehydrogenase activity in isolated mouse heart 
mitochondria
The activity of ALDH-2 in isolated mitochondria was
determined by measuring the conversion of 2-hydroxy-3-
nitro-benzaldehyde to 2-hydroxy-3-nitro-benzoic acid
using a modified published protocol [22]. The mitochon-
drial suspension was diluted to approximately 1 mg/ml
protein in PBS and 2-hydroxy-3-nitro-benzaldehyde (100
μM) was added and the samples were incubated for 30
min at 37°C. 100 μl of each sample were subjected to
HPLC analysis.
Effects of GTN and PETN on HO-1 mRNA expression in 
cultured EA.hy 926 cells
Human endothelial cells EA.hy 926 cells [32] were grown
in Dulbecco's modified Eagle's medium (Sigma) with
10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium
pyruvate, 100 IU/ml penicillin, 100 μg/ml streptomycin,
and 1× HAT (hypoxanthine, amethopterin/methotrexate,
thymine) [33]. Confluent cells (6-well plates) were incu-
bated with either DMSO (0.1 %), 10 μM PETN, 50 μM
PETN or ethanol (0.1 %), 10 μM GTN, 50 μM GTN for 12
h. mRNA expression of HO-1 was analyzed with quantita-
tive real-time RT.
Briefly, total RNA from EA.hy926 cells was isolated
according to the manufacturer's protocol (RNeasy Mini
Kit; Qiagen, Hilden, Germany). 0.5 μg of total RNA was
used for real-time RT-PCR analysis with the QuantiTect™
Probe RT-PCR kit (Qiagen) in 25 μl reactions in a 96-well
spectrofluorometric thermal cycler (iCycler, Bio-Rad,
München, Germany). Real-time qRT-PCR was performed
according to the manufacturer's recommendations using
the oligonucleotides listed below (all from MWG-Biotech,
Ebersberg, Germany).
HO-1
sense AGGCCAAGACTGCGTTCCT
antisense GGCTCTGGTCCTTGGTGTCAT
probe CTCAACATCCAGCTCTTTGAGGAGTTGCAG
GAPDH
sense CCCATGTTCGTCATGGGTGT
antisense TGGTCATGAGTCCTTCCACGATA
probe CTGCACCACCAACTGCTTAGCACCC
Each experimental reaction was performed in triplicate.
All primer/probe sets had efficiencies of 100% (± 10%).
The comparative Ct method was used for relative mRNA
quantification [34]. Gene expression was normalized to
the endogenous control, GAPDH mRNA, and the amount
of target gene mRNA expression in each sample was
expressed relative to that of control.
Statistical Analysis
Results are expressed as mean ± SEM. One-way ANOVA
(with Bonferroni's or Dunn's correction for comparison
of multiple means) was used for comparisons of vasodila-
tor potency and efficacy, L-012-derived chemilumines-
cence, ALDH-2 activity as well as HO-1 mRNA expression.
The EC50 value for each experiment was obtained by log-
transformation. P values < 0.05 were considered signifi-
cant. * indicates significance vs. solvent control.
Results
Effect of heterozygous deficiency in mitochondrial 
superoxide dismutase (Mn-SOD+/-) on vasodilator 
responses in response to organic nitrate treatment
We here show for the first time data from isometric ten-
sion studies indicating that a partial (50 %) deficiency in
Mn-SOD and accordingly increased basal mitochondrial
ROS levels result in a more pronounced clinical tolerance.
This phenomenon was characterized by impaired vasodi-
lator potency of GTN and a significant right-shift of the
concentration-relaxation curve (Figure 1A). Similar effects
were observed for the concentration-relaxation curves of
the endothelium-dependent vasodilator ACh as well as
the nitrovasodilator isosorbide dinitrate (ISDN), indicat-
ing mild but not significant cross-tolerance to these com-
pounds in GTN-treated Mn-SOD vessels (see Table 1). It is
important to note that the GTN in vivo dose was adjusted
as compared to previous studies to cause no severe toler-
ance in wild type control mice. Accordingly, GTN in vivo
treatment of wild type mice with this low nitrate dose
resulted in mild tolerance to GTN but obviously no cross-
tolerance to ACh and ISDN (Table 1). In contrast, PETN in
vivo  treatment resulted in no clinical tolerance and we
observed normal PETN and ACh potencies in vessels from
wild type and Mn-SOD+/- mice (Figure 1B, Table 1). Nev-
ertheless, the PETN concentration-response-curve which
was performed prior to the GTN concentration-response-
curve resulted in decreased potency of GTN (Table 1). This
indicates that in vitro incubation with the concentration of
PETN that caused 100 % relaxation (ED100 = 31.6 μM)
induced in vitro tolerance (tachyphylaxis) to the finallyBMC Cardiovascular Disorders 2006, 6:44 http://www.biomedcentral.com/1471-2261/6/44
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applied nitrate GTN. The GTN potency in this subsequent
concentration-relaxation-curve was shifted by more than
one log as compared to normal GTN potency in mouse
aorta (see wild type in Table 1).
Effect of heterozygous deficiency in mitochondrial 
superoxide dismutase (Mn-SOD+/-) and bilirubin levels on 
mitochondrial oxidative stress in response to organic 
nitrate treatment
In accordance to the vascular responses, mitochondrial
ROS was not increased but rather decreased in PETN-
treated Mn-SOD+/- mice (Figure 2B). This was an impor-
tant finding with respect to our recent observation that
mitochondrial ROS levels were significantly increased
upon GTN in vivo treatment of Mn-SOD+/- mice [23]
which was reproduced with the present findings (Figure
2A). Since the applied GTN dose was low, wild type mito-
chondria showed no increased ROS formation in
response to GTN in vivo treatment which could be best
explained by antioxidant properties of the small amounts
of the solvent ethanol. Ethanol in turn could interfere
with GTN bioactivation by the formation of the natural
substrate and competitive inhibitor of bioactivation
acetaldehyde.
Mitochondrial ROS were increased by almost 50 % in
response to GTN in vivo treatment of Wistar rats (Figure
2C). Bilirubin concentration-dependently decreased the
chemiluminescence signal in mitochondria from GTN-
treated Wistar rats indicating its potent scavenging proper-
ties for GTN-derived ROS (Figure 2C).
Effect of heterozygous deficiency in mitochondrial 
superoxide dismutase (Mn-SOD+/-) on mitochondrial 
ALDH-2 activity in response to organic nitrate treatment
GTN  in vivo treatment decreased the redox-sensitive
ALDH-2 activity in isolated heart mitochondria from Mn-
SOD+/- mice (30.4 ± 1.5 in ethanol group vs. 21.4 ± 1.5 in
GTN group, n = 25–27, p < 0.001) whereas PETN slightly
(although not significantly) increased the ALDH-2 activity
(39.8 ± 3.3 in DMSO group vs. 42.3 ± 4.4 in PETN group,
n = 9, p = 0.647).
Effects of GTN and PETN on HO-1 mRNA expression in 
cultured EA.hy 926 cells
PETN concentration-dependently increased the HO-1
mRNA levels in EA.hy 926 cells resulting in a significant
increase at 50 μM (Figure 3). In contrast, GTN only
induced a minor increase in HO-1 mRNA which did not
reach significance (Figure 3). Similar differences have pre-
viously been demonstrated between the PETN trinitrate
metabolite PETriN and ISDN [26,27].
Discussion
Nitrate tolerance and the "oxidative stress concept"
Previous studies have demonstrated that nitrate tolerance
in response to GTN in vivo treatment is a multifactorial
phenomenon [2]. The "oxidative stress concept" in the
setting of nitrate tolerance was established by our group
[3] and refined during the last couple of years [4,23]. In
essence, the concept consists of increased superoxide for-
mation in response to nitrate treatment which decreases
NO bioavailability, leads to peroxynitrite formation [8],
NOS uncoupling [35] and impairs NO/cGMP signaling
[4]. Moreover, oxidative inhibition of prostacyclin syn-
thase [18] as well as mitochondrial ALDH activity [22]
may present other key events in the development of
nitrate tolerance. In the present study we demonstrate that
low dose GTN for 4 d causes tolerance (indicated by a sig-
nificant right-shift in GTN concentration-relaxation-
curve) in Mn-SOD+/- mice but has only minor effects on
GTN potency and efficacy in wild type mice (Figure 1A).
Also mild cross-tolerance to ACh and ISDN was observed
(Table 1). In contrast, PETN which has been reported to
possess protective effects, caused no tolerance (Figure 1B
and Table 1).
Inhibition of ALDH-2 and mitochondrial ROS formation
Recently, we have identified the mitochondria as a major
source of oxidative stress in tolerant animals [16,21,22].
These results are in accordance with the observation that
the mitochondrial ALDH provides an important bioacti-
vation pathway for GTN [19,20,24,25] and is redox-sensi-
tive [36,37] (see scheme in Figure 4). These facts provide
a new link between oxidative stress and impaired GTN
bioactivation and accordingly development of tolerance:
Mitochondrial ROS oxidatively inactivate the ALDH-2.
The involvement of mitochondria in the development of
nitrate tolerance was previously postulated by the "thiol
concept" of Needleman and coworkers [38,39]. An inter-
esting link between mitochondrial oxidative stress trig-
gered ALDH-2 inhibition and activation of vascular
NADPH oxidases could be the accumulation of toxic alde-
hydes (as observed in ALDH-2-/- mice). It was reported
that low concentrations of 9-hydroxynonenal may stimu-
late whereas high concentrations may inhibit NADPH
oxidase activity and/or expression [40]. In the present
study we could demonstrate that GTN treatment resulted
in an increase in mitochondrial ROS and a decrease in
ALDH-2 activity in the Mn-SOD+/- mice whereas PETN did
not significantly alter these parameters (Figure 2 and
Results).
Diversity of organic nitrates with respect to induction of 
oxidative stress and clinical tolerance
The tetranitrate PETN was previously shown to cause no
induction of clinical tolerance and vascular oxidative
stress [12,14,17]. The beneficial properties of PETN wereBMC Cardiovascular Disorders 2006, 6:44 http://www.biomedcentral.com/1471-2261/6/44
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Vasodilator responses of isolated aortic vessel segments upon chronic treatment of wild type and Mn-SOD+/- mice with GTN  or PETN Figure 1
Vasodilator responses of isolated aortic vessel segments upon chronic treatment of wild type and Mn-SOD+/- 
mice with GTN or PETN. (A) Concentration-relaxation curves for GTN (10-9 to 10-4.5 M) in vessels from wild type and 
Mn-SOD+/- mice upon treatment with ethanol or GTN in ethanol. The symbols are closed circles (ethanol infused wild type), 
closed triangles (GTN infused wild type), open circles (ethanol infused Mn-SOD+/-) and open triangles (GTN infused Mn-SOD+/
-). Data are mean ± SEM of 7–10 independent experiments. (B) Concentration-relaxation curves for PETN (10-10 to 10-4.5 M) in 
vessels from wild type and Mn-SOD+/- mice upon treatment with DMSO or PETN in DMSO. The symbols are closed circles 
(DMSO infused wild type), closed triangles (PETN infused wild type), open circles (DMSO infused Mn-SOD+/-) and open trian-
gles (PETN infused Mn-SOD+/-). Data are mean ± SEM of 6–8 independent experiments.BMC Cardiovascular Disorders 2006, 6:44 http://www.biomedcentral.com/1471-2261/6/44
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explained by induction of the antioxidative proteins ferri-
tin and HO-1 [26,27] which may prevent oxidative stress
and protect the vasculature from oxidative damage [2]
and thereby mimic the antioxidant principle of com-
pounds such as hydralazine [16]. HO-1 has been demon-
strated to be a major protective and antioxidative
principle in numerous therapeutic interventions [41,42].
The underlying mechanism of this protection is thought
to be based on the breakdown of porphyrins to yield the
potent antioxidant bilirubin [43-45] and the anti-inflam-
matory compound carbon monoxide [46,47] which is a
weak activator of soluble guanylyl cyclase [48]. This is of
special interest since HO-1 was reported to be localized
within mitochondria [49] and thereby could directly
affect nitrate-induced mitochondrial ROS formation and
protect ALDH-2 from oxidative inactivation (see scheme
in Figure 4).
There is growing body of evidence that ALDH-2 only bio-
activates tri- and tetranitrates which show high potency in
tension studies. During reduction of nitrates the dithiol
groups at the active site of the enzyme form a disulfide
bridge causing its inactivation. Dihydrolipoic acid is able
to restore enzymatic activity (Daiber et al., unpublished
observations) but needs reduction by appropriate
enzymes. It is thought that GTN induces mitochondrial
ROS formation which may contribute to oxidative inhibi-
tion of ALDH-2 activity and depletion of reduced thiols
(such as dihydrolipoic acid) [38] thereby disrupting the
physiological catalytic cycle (Figure 4). According to
numerous reports in the literature PETN displays potent
antioxidative properties which are probably based on the
afore mentioned formation of bilirubin, CO and ferritin
(Figure 4). In the present study we could demonstrate that
bilirubin efficiently decreases mitochondrial oxidative
stress in response to GTN treatment (Figure 2C). Moreo-
ver, we could reproduce previous results of Oberle et al.
on PETN-triggered HO-1 induction and more importantly
demonstrate that this inducing effect is not shared by GTN
(Figure 3). This, however, could provide an explanation
for the differences in tolerance induction by both organic
nitrates.
One would expect that all NO donors induce HO-1 since
this gene is heavily regulated by NO. However, previous
publications have demonstrated that HO-1 inducing
capacity is not shared by all NO donors [50]. It is unclear
why ISDN and GTN do not induce HO-1. Especially, since
HO-1 is regulated by at least 3 important transcription fac-
tors (NFκB, AP-1, Nrf2/Keap1) and induced by a huge
number of different stimuli [51] providing many regula-
tory sites, which could explain the different properties of
ISDN and GTN versus PETN. At this stage we have no
hypothesis to explain these differences in vitro.
Conclusion
The results obtained in Mn-SOD+/- mice clearly indicate
that mitochondrial ROS play an important role for the
development/maintenance of nitrate tolerance. The
results obtained with PETN indicate that organic nitrates
differ markedly and that protective antioxidative proper-
ties (mediated by HO-1 and derived bilirubin) may com-
pensate for harmful induction of oxidative stress sources.
Abbreviations
ACh:  acetylcholine,  ALDH-2:  mitochondrial aldehyde
dehydrogenase,  ECL:  enhanced chemiluminescence,
GTN: glyceryl trinitrate (nitroglycerin), HO-1: heme oxy-
genase-1, ISDN: isosorbide dinitrate, L-012: 8-amino-5-
chloro-7-phenylpyrido [3,4-d]pyridazine-1,4-
(2H,3H)dione sodium salt, Mn-SOD: manganese super-
oxide dismutase (mitochondrial isoform), Mn-SOD+/-:
heterozygous Mn-SOD deficiency, PETN: pentaerithrityl
tetranitrate, ROS: reactive oxygen species.
Table 1: Vasodilator potency of ACh, GTN, PETN and ISDN in vessels from wild type or Mn-SOD+/- mice upon chronic treatment with 
GTN or PETN.
Potency, EC50 (-log M) a
In Vivo Treatment ACh PETN GTN ISDN
WT/EtOH 6.97 ± 0.2 (n = 7) n.d. 6.98 ± 0.1 (n = 9) 4.44 ± 0.1 (n = 4)
WT/GTN 7.05 ± 0.2 (n = 8) n.d. 6.44 ± 0.1 (n = 7)* 4.55 ± 0.1 (n = 4)
Mn-SOD+/-/EtOH 7.16 ± 0.1 (n = 10) n.d. 6.68 ± 0.1 (n = 8) 4.38 ± 0.1 (n = 4)
Mn-SOD+/-/GTN 6.86 ± 0.1 (n = 9) n.d. 5.77 ± 0.1 (n = 10)*# 4.17 ± 0.1 (n = 4)*
WT/DMSO 6.89 ± 0.1 (n = 7) 6.82 ± 0.3 (n = 6) 5.64 ± 0.2 (n = 7) n.d.
WT/PETN 7.26 ± 0.0 (n = 5)§ 6.57 ± 0.2 (n = 6) 5.97 ± 0.3 (n = 6) n.d
Mn-SOD+/-/DMSO 7.12 ± 0.1 (n = 7) 6.55 ± 0.2 (n = 7) 5.70 ± 0.2 (n = 7) n.d.
Mn-SOD+/-/PETN 7.30 ± 0.1 (n = 8)§ 6.37 ± 0.1 (n = 8) 5.71 ± 0.1 (n = 8) n.d
a *, p < 0.05 vs. WT/EtOH and #, p < 0.05 vs. Mn-SOD+/-/EtOH.
§, p < 0.05 vs. WT/DMSO and$, p < 0.05 vs. Mn-SOD+/-/DMSO.
n.d. means not determined.BMC Cardiovascular Disorders 2006, 6:44 http://www.biomedcentral.com/1471-2261/6/44
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Mitochondrial ROS formation upon chronic treatment of wild type and Mn-SOD+/- mice with GTN or PETN and effects of  bilirubin Figure 2
Mitochondrial ROS formation upon chronic treatment of wild type and Mn-SOD+/- mice with GTN or PETN 
and effects of bilirubin. (A) Mitochondrial ROS formation was stimulated with succinate (2 mM) and measured by L-012 
(100 μM) ECL in hearts from wild type and Mn-SOD+/- mice upon treatment with ethanol or GTN in ethanol. Data are mean ± 
SEM of 4 independent experiments. * P < 0.05 vs. WT/EtOH and # P < 0.05 vs. MnSOD/EtOH. (B) Mitochondrial ROS forma-
tion was stimulated with succinate (2 mM) and measured by L-012 (100 μM) ECL in hearts from wild type and Mn-SOD+/- mice 
upon treatment with DMSO or PETN in DMSO. Data are mean ± SEM of 16 independent experiments. * P < 0.05 vs. WT/
DMSO. (C) Bilirubin efficiently decreased mitochondrial ROS (L-012 ECL) in response to GTN in vivo treatment of Wistar 
rats. Data are mean ± SEM of 6–11 independent experiments. # P < 0.05 vs. control, * P < 0.05 vs. GTN in vivo group.BMC Cardiovascular Disorders 2006, 6:44 http://www.biomedcentral.com/1471-2261/6/44
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HO-1 mRNA expression in EA.hy 926 cells in response to PETN or GTN treatment Figure 3
HO-1 mRNA expression in EA.hy 926 cells in response to PETN or GTN treatment. Confluent cells were incu-
bated with the solvent (DMSO or ethanol) or PETN as well as GTN for 12 h. PETN but not GTN resulted in a significant 
increase in HO-1 mRNA. Data are mean ± SEM of at least 3 independent experiments. * P < 0.05 vs. control.
Proposed mechanism for organic nitrate bioactivation, induction of oxidative stress and protective effects Figure 4
Proposed mechanism for organic nitrate bioactivation, induction of oxidative stress and protective effects. 
Highly potent organic nitrate (tri- and tetranitrates) are bioactivated by mitochondrial ALDH. The bioactivation (reduction 
cycle) requires two thiol groups at the active site of the enzyme which are oxidized to the disulfide during the conversion 
which yields the denitrated metabolite and an NOx species that is similar to NO. Enzymatic activity is restored by reduced 
lipoic acid/lipoamide which is recycled by lipoamide reductase (LAR), thioredoxin/thioredoxin reductase system (Trx/TrxR) or 
glutathione/glutathionereductase system (GSH/GR). GTN leads to mechanism-based inactivation of the enzyme but also trig-
gers mitochondrial oxidative stress which may directly inactivate mtALDH, deplete dihydrolipoic acid or interfere with its 
reductases. In contrast, PETN induces HO-1 which by breakdown of porphyrins yields the potent antioxidant bilirubin, the 
anti-inflammatory compound CO and induces ferritin, another protective enzyme which decreases free iron and prevents Fen-
ton-type reactions.BMC Cardiovascular Disorders 2006, 6:44 http://www.biomedcentral.com/1471-2261/6/44
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